Highlighting High Growth Tech Stocks In November 2024

In This Article:

In the wake of a "red sweep" in the U.S. elections, global markets have seen significant shifts, with major indices like the Russell 2000 and S&P 500 experiencing notable gains due to investor optimism about potential economic growth and regulatory changes. As small-cap stocks rally amidst these developments, identifying high-growth tech stocks becomes crucial for investors looking to capitalize on market momentum; such stocks often exhibit strong innovation potential and adaptability to changing economic landscapes.

Top 10 High Growth Tech Companies

Name

Revenue Growth

Earnings Growth

Growth Rating

Material Group

20.45%

24.01%

★★★★★★

Yggdrazil Group

24.66%

85.53%

★★★★★★

eWeLLLtd

26.52%

27.53%

★★★★★★

Ascelia Pharma

76.15%

47.16%

★★★★★★

Medley

26.75%

31.99%

★★★★★★

Seojin SystemLtd

33.39%

49.13%

★★★★★★

Alkami Technology

21.89%

98.60%

★★★★★★

Mental Health TechnologiesLtd

27.88%

79.61%

★★★★★★

TG Therapeutics

34.66%

56.48%

★★★★★★

UTI

114.97%

134.60%

★★★★★★

Click here to see the full list of 1279 stocks from our High Growth Tech and AI Stocks screener.

Let's review some notable picks from our screened stocks.

Celltrion

Simply Wall St Growth Rating: ★★★★★☆

Overview: Celltrion, Inc., along with its subsidiaries, focuses on developing and producing protein-based drugs for oncology treatment in South Korea and has a market capitalization of approximately ₩34.34 trillion.

Operations: Celltrion, Inc. generates revenue primarily from two segments: Chemical Drugs and Bio Medical Supply, with the latter contributing significantly more at ₩3.54 trillion. The company specializes in protein-based oncology treatments within South Korea.

Despite a challenging year with earnings down by 40.4%, Celltrion's future looks promising, underscored by a robust pipeline and strategic buybacks. The company has committed to repurchasing up to 537,924 shares to stabilize stock prices and enhance shareholder value, reflecting confidence in its financial health. Moreover, Celltrion is poised for significant growth with expected annual revenue and earnings growth rates of 26.3% and 61%, respectively—outpacing the Korean market projections substantially. This growth trajectory is supported by recent approvals like ZYMFENTRA® in the U.S., enhancing its competitive edge in biologics for inflammatory diseases.

KOSE:A068270 Revenue and Expenses Breakdown as at Nov 2024
KOSE:A068270 Revenue and Expenses Breakdown as at Nov 2024

Sonata Software

Simply Wall St Growth Rating: ★★★★★☆

Overview: Sonata Software Limited, along with its subsidiaries, offers information technology services and solutions across various regions including the United States, Europe, the Middle East, Asia, India, and Australia with a market capitalization of ₹159.30 billion.